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Polymer based nanoparticle formulations have been shown to increase drug
bioavailability and/or reduce drug adverse effects. Nonsteroidal anti-inflammatory
drugs (e.g. celecoxib) reduce prostaglandin synthesis and cause side effects such
as gastrointestinal and renal complications. The aim of this study was to formulate
celecoxib entrapped poly lactide-co-glycolide based nanoparticles through a
solvent evaporation process using didodecyldimethylammonium bromide or poly
vinyl alcohol as stabilizer. Nanoparticles were characterized for zeta potential,
particle size, entrapment efficiency, and morphology. Effects of stabilizer
concentration (0.1, 0.25, 0.5, and 1% w/v), drug amount (5, 10, 15, and 20 mg), and
emulsifier (lecithin) on nanoparticle characterization were examined for formula
optimization. The use of 0.1, 0.25, and 0.5% w/v didodecyldimethylammonium
bromide resulted in a more than 5-fold increase in zeta potential and a more than
1.5-fold increase in entrapment efficiency with a reduction in particle size over 35%,
when compared to stabilizer free formulation. Nanoparticle formulations were also
highly influenced by emulsifier and drug amount. Using 0.25% w/v
didodecyldimethylammonium bromide NP formulations, peak zeta potential was
achieved using 15 mg celecoxib with emulsifier (17.15¡0.36 mV) and 20 mg
celecoxib without emulsifier (25.00¡0.18 mV). Peak NP size reduction and
entrapment efficiency was achieved using 5 mg celecoxib formulations with
(70.87¡1.24 nm and 95.55¡0.66%, respectively) and without (92.97¡0.51 nm
and 95.93¡0.27%, respectively) emulsifier. In conclusion, formulations using 5 mg
celecoxib with 0.25% w/v didodecyldimethylammonium bromide concentrations
produced nanoparticles exhibiting enhanced size reduction and entrapment
efficiency. Furthermore, emulsifier free formulations demonstrated improved zeta
potential when compared to formulations containing emulsifier (p,0.01). Therefore,
our results suggest the use of emulsifier free 5 mg celecoxib drug formulations
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containing 0.25% w/v didodecyldimethylammonium bromide for production of
polymeric NPs that demonstrate enhanced zeta potential, small particle size, and
high entrapment efficiency.

Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are well established for the
treatment of pain and inflammation. They function by acting on the cyclooxygenase (COX) family of enzymes and inhibiting the conversion of arachidonic
acid to prostaglandins and thromboxanes [1, 2]. The COX enzyme exists as at least
two different isozymes, COX-1 and COX-2. The COX-1 enzyme is constitutively
expressed in most tissue and functions to regulate hemodynamics and maintain
gut integrity. COX-2 is an inducible enzyme found primarily at sites of
inflammation that mediates fever and pain [3–5]. COX-2 has been found to be
constitutively expressed in certain tissue such as the kidneys, the reproductive
tract, and gastric mucosa [6–9]. Traditionally, NSAIDs function by inhibiting
both COX-1 and COX-2 isozymes and provide analgesic and anti-inflammatory
benefits. These benefits are thought to arise primarily from the inhibition of COX2, while the adverse effects (e.g. ulceration) were thought to occur from over
inhibition of COX-1 [10–12]. As a result, COX-2-selective inhibitors (COXIBs)
were developed to provide analgesic and anti-inflammatory benefits, while
minimizing the gastrointestinal adverse side effects associated with traditional
NSAID use [10, 13].
Celecoxib (CEL) is a COXIB used in the treatment of pain and inflammation
[11, 12, 14]. Evidence suggests that CEL use effectively reduces clinical gastrointestinal events in comparison to other NSAIDs, making it one of the most
commonly prescribed COX-2 specific inhibitors [15–17]. Despite the general
safety of CEL in regard to gastrointestinal tolerability, its use has been associated
with the development of several adverse side effects including cardiovascular
events, and renal toxicity [17, 18]. Many CEL delivery systems have been
developed to reduce CEL associated side effects [19–22]. Studies utilizing
nanoparticle (NP) formulations have shown promising results in overcoming high
dose oral administration of CEL [21, 23–25]. One study showed enhanced drug
retention at the site of action following intra-articular injection of small lipid
nanoparticle formulated CEL in the treatment of joint pain [26]. Another study
showed enhanced anti-inflammatory effects of CEL utilizing NP formulated
transdermal drug delivery [27]. A third study showed enhanced inhibition of
tumor growth with a reduction in side effects using hydroxyapatite-chitosan
nanocomposited CEL in the treatment of colon cancer [28].
Polymer based NPs are commonly used to improve drug bioavailability and/or
reduce drug associated side effects [29]. Poly lactide-co-glycolide (PLGA) is a
polymer that has been commercialized for a variety of drug delivery systems and is

PLOS ONE | DOI:10.1371/journal.pone.0113558 December 12, 2014

2 / 22

Nanoparticle Formulation of Celecoxib

frequently used in the design of biocompatible NPs [30]. PLGA is approved by the
Food and Drug Administration as a biodegradable polymer that degrades to the
nontoxic tricarboxylic acid cycle intermediates, lactic acid and glycolic acid
[30–32]. Use of PLGA based NPs for enhanced delivery of CEL has been met with
a variety of results [19, 20]. However, known NP stabilizers such as
didodecyldimethylammonium bromide (DMAB) and poly vinyl alcohol (PVA)
have yet to be used in the development of CEL loaded PLGA-NPs.
Previous studies have shown effective use of DMAB and PVA for formulation
of small, highly entrapped NPs [33, 34]. The aim of this study was to characterize
and optimize CEL loaded PLGA-NPs by examining the influence of varying
DMAB and PVA concentrations on NP characterstics. The effect of drug amount
and emulsifier (lecithin) on zeta potential, particle size, entrapment efficiency,
morphology, and stability was also examined.

Materials and Methods
Materials
DMAB, PVA (MW 89,000–98,000 Da, 99.9+% hydrolyzed), PLGA (50:50
copolymer compositions; MW 30,000–60,000 Da), and lecithin (99% phosphatidylcholine) were purchased from Sigma-Aldrich (St. Louis, MO, USA). CEL base
powder was obtained from Biovision Incorporated (Milpitus, CA, USA). Acetone,
ethyl acetate, and high-performance liquid chromatography (HPLC)-grade water
were purchased from Fischer Scientific Laboratory (Fair Lawn, NJ, USA).

Preparation of CEL loaded PLGA-NPs
NP formulations were carried out using a previously described solvent
evaporation technique [33, 35]. CEL-loaded NPs were formulated by dissolving
20 mg of CEL and 50 mg PLGA into 3 mL of ethyl acetate. The solution was
stirred for 30 minutes at 750 rpm. Afterwards, 30 mg of lecithin was added to the
organic solution followed by addition of 500 mL acetone as co-solvent. A varying
range of DMAB or PVA concentrations (0.1%, 0.25%, 0.5%, and 1% w/v) was
dissolved in 6 mL of HPLC grade water. Organic phase was then added to
aqueous phase in a drop wise manner under moderate stirring followed by
sonication for 5 minutes at 20 KHz. After sonication, solutions were stirred at
750 rpm for 1 hour to evaporate organic phase. Emulsions were then centrifuged
at 12,000 rpm followed by separation of supernatant from precipitants.
Additional NP formulations for optimization studies were carried out with 0.25%
w/v DMAB concentration. Using the previously described process, emulsifier free
CEL loaded PLGA-NPs were formulated with the exclusion of lecithin; while NP
preparation for observing the effects of drug amount was carried out using various
amounts of CEL (5, 10, 15, and 20 mg).
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Particle size and zeta potential of CEL-loaded NPs
Intensity weighted mean particle size (diameter) was measured in triplicate by
dynamic light scattering using a NICOMP particle sizer (Particle Sizing Systems,
Port Richy, FL, USA). Zeta potential was estimated on the basis of electrophoretic
mobility under an electrical field.

Drug entrapment efficiency
To measure drug entrapment efficiency, 100 mL NP formulation was added to
300 mL acetonitrile and vortex mixed for 30 seconds. Afterwhich, 100 mL of drug
loaded NP solution was analyzed under ultraviolet–visible spectroscopy
(Eppendorf Biophotometer, Hauppauge, NY, USA) at 260 nm using empty NP
solutions as blank. A standard calibration curve (50,000–2,000,000 ng/mL) was
constructed using titrated dilutions of CEL stock solution dissolved in acetonitrile.
Drug entrapment efficiency was calculated using the following equation:
Entrapment efficiency (%) 5 (Amount of CEL entrapped within nanoparticles/
Total amount of CEL used for formulation) 6100

Morphology
Transmission electron microscopy (TEM) (Tecnai Philips Transmission Electron
Microscope; FEI, Hillsboro, Oregon, USA) was used for evaluation of CEL loaded
PLGA-NP shape and surface morphology. NP emulsions were vortex mixed and
2 mL aliquots were placed on a 200 mesh copper grid covered with Formvar film
(Electron Microscopy Sciences, Hatfield, Pennsylvania). Samples were air dried
for 1 hour then examined at 80 kV.

Stability of CEL loaded PLGA-NPs
CEL loaded PLGA-NP emulsions (5 mL) formulated at various drug amounts (5,
10, 15, and 20 mg) with or without emulsifier (0.25% w/v DMAB) were stored at
4 ˚C for a period of 16 weeks. After 16 weeks samples were removed from storage
and analyzed for particle size, zeta potential, and drug entrapment efficiency.
Particle characteristics were evaluated as previously described.

Data analysis
All experiments were performed in triplicate. NP characteristic data is represented
as mean ¡ standard deviation (SD). A Student’s t-test was used for comparison
of two groups.
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Results and Discussion
Effect of stabilizer concentration on NP characteristics
CEL encapsulated PLGA-NPs were developed using lecithin as an emulsifier with
DMAB or PVA (Table 1). The use of DMAB or PVA resulted in formation of CEL
loaded PLGA-NPs with surface characteristics that displayed positive and negative
charges, respectively (Fig. 1). Because of the cationic properties of DMAB
[36–38], NPs formulated with inclusion of DMAB showed highly positive surface
charges (Fig. 1A). DMAB formulated CEL loaded NPs reached a peak zeta
potential of 20.03¡0.84 mV at 0.5% w/v concentration. The anionic characteristics of PVA led to the formation of NPs with slightly negative surface charges
(Fig. 1B). PVA formulated NPs reached a peak zeta potential of 26.09¡1.39 mV
with 0.25% w/v concentration.
When comparing zeta potential as a measure of stability, all CEL-NP
formulations containing DMAB or PVA showed significant alterations in NP
system stability compared to stabilizer free formulations (plain formulation)
(Fig. 1A and Fig. 1B). These results are indicative of altered NP characteristics as a
result of adsorption or inclusion of DMAB and PVA onto or within the NP
polymer shell. The inclusion of cationic and anionic DMAB (Fig. 1A) or PVA
(Fig. 1B) on NP surfaces can effectively alter overall NP charge, in turn, effecting
overall system stability [38–40].
In comparison to plain formulation, a significant reduction in particle size was
seen in formulations incorporating 0.1%, 0.25%, and 0.5% DMAB (Fig. 2).
Particle size was significantly increased in 1% DMAB concentrations when
compared to plain formulation. The largest reduction in particle size was achieved
using 0.25% DMAB concentration (99.97¡3.27 nm) (p,0.01). High concentrations of DMAB have been shown to increase system viscosity, resulting in a
direct increase in particle size [41], which may explain the significant rise in
particle size noticed with CEL-NPs formulated using larger amounts of stabilizer.
Furthermore, DMAB can act as a solubilizing agent for known hydrophobic
compounds [35]. It is possible that lower DMAB concentrations may act to
effectively reduce drug crystallization, further reducing NP size, which may
explain NP size reductions seen in our study with lower DMAB concentrations
(Fig. 2). Conversely, a significant increase in CEL solubility brought forth by
higher DMAB content could also function to increase NP drug loading capacity
and increase particle size by means of expanding NP drug content within the
polymer shell.
Formulations using 0.1% w/v PVA did not demonstrate any significant
difference in particle size when compared to plain formulation (p.0.77). Particle
size measurements of 0.25%, 0.5% and 1% PVA formulations were not detectable
by our NICOMP particle sizer due to reduced entrapment efficiency and total
drug concentrations in PVA based NP solution.
The amount entrapped (1.99¡0.01 mg) and entrapment efficiency
(9.94¡0.01%) of CEL in formulations without stabilizer were compared to
DMAB and PVA based formulations (Table 2). All stabilizer based formulations
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Table 1. NP formulation with varying concentrations of DMAB or PVA.
Formulation Number

*

Ingredients
Ethyl acetate (mL)

Water (mL)

DMAB (% PVA
PLGA
w/v)
(% w/v) (mg)

Acetone
(mL)

1*

3

6

-

-

50

500

20

30

2

3

6

0.1

-

50

500

20

30

3

3

6

0.25

-

50

500

20

30

4

3

6

0.5

-

50

500

20

30

5

3

6

1

-

50

500

20

30

6

3

6

-

0.1

50

500

20

30

7

3

6

-

0.25

50

500

20

30

8

3

6

-

0.5

50

500

20

30

9

3

6

-

1

50

500

20

30

Celecoxib(mg)

Lecithin
(mg)

Stabilizer free (plain) formulation.

doi:10.1371/journal.pone.0113558.t001

demonstrated significant changes in entrapment efficiency when compared to
plain formulation (Table 2) (P,0.01). All DMAB formulations and 0.1% PVA
formulation exhibited significant increases in the level of CEL entrapment with a
maximum percent entrapment of 61.07¡0.06% reached with 1% DMAB
formulation. All PVA concentrations above 0.1% w/v underwent a significant
reduction in drug entrapment (Table 2). The reduction in drug entrapment can
be explained by elucidation of PVA properties. PVA is a highly hydrophilic
stabilizer, which can result in reduced NP stability in aqueous solutions [42]. As
PVA concentrations increase, the hydrophilic nature of the NP system increases.
The increased inclusion of PVA into the NP polymer shell could increase
hydrophilic properties leading to NP solubilization in the aqueous medium
following organic phase evaporation. The increased hydrophilic properties of
PVA-NP systems could reduce entrapment efficiency leading to an increased loss
of drug in solution precipitant following centrifugation.
In this study, DMAB was shown to effectively increase zeta potential, reduce
particle size, and facilitate drug entrapment when compared to PVA based
formulations. As such, DMAB based NP morphology was visualized and
confirmed under transmission electron microscopy (TEM) (S1 Figure) with
further variable analysis carried out using DMAB formulations.

Analysis of NP characteristics in absence of emulsifier
To analyze the effect of emulsifier on CEL loaded NP characteristics, formulations
containing 0.1%, 0.25%, 0.5%, and 1% w/v DMAB without lecithin were
developed, characterized, and compared to previously observed characteristics of
NP formulations with lecithin (Fig. 3). NP visual identification of emulsifier free
formulations was performed via TEM analysis (S2 Figure). When compared to
emulsifier based formulations, absence of emulsifier resulted in a significant
increase of zeta potential in formulations using 0.25%, 0.5%, and 1% stabilizer
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Fig. 1. Zeta potential measurements of A) DMAB and B) PVA formulated NPs of celecoxib. Values are
expressed as mean ¡ SD, n53. *p,0.05, significantly different from plain formulation.
doi:10.1371/journal.pone.0113558.g001

concentrations (Fig. 3A) (P,0.01). These findings indicate that the use of an
emulsifier may function to reduce overall particle repulsion and system stability.
The cationic property of DMAB has become increasingly popular for development
of positively charged NPs [43]. In emulsifier free formulations, we found that
rising zeta potential was associated with increased DMAB concentration. These
results can be indicative of enhanced DMAB inclusion into the NP polymer shell.
Furthermore, lecithin contains low concentrations of phosphatidic acid. The
presence of phosphatidic acid can impart negatively charged, anionic characteristics during inclusion into NP formulations [44]. As such, the anionic properties

PLOS ONE | DOI:10.1371/journal.pone.0113558 December 12, 2014
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Fig. 2. Particle size analysis of increasing concentrations of DMAB compared to formulation without stabilizer (plain formulation). Values are
expressed as mean ¡ SD, n53. *p,0.05, significantly different from plain formulation.
doi:10.1371/journal.pone.0113558.g002

Table 2. Effects of stabilizer concentrations on celecoxib entrapment.
Stabilizer

Conc. (% w/v)

AE (mg)

EE (%)

Stabilizer free

0

1.99¡0.01

9.94¡0.01

DMAB

0.1

3.78¡0.01

18.85¡0.07*

0.25

9.94¡0.08

49.70¡0.38*

0.5

6.16¡0.01

30.84¡0.04*

1

12.22¡0.01

61.07¡0.06*

0.1

9.23¡0.03

46.19¡0.16*

0.25

0.11¡0.02

0.56¡0.03*

0.5

0.06¡0.01

0.33¡0.02*

1

0.66¡0.03

3.28¡0.14*

PVA

All values reported as mean ¡ SD (n53). Amount entrapped (AE) per 20 mg celecoxib. EE is the entrapment efficiency.
*
P,0.01 compared to plain formulation.
doi:10.1371/journal.pone.0113558.t002
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Fig. 3. Nanoparticle characteristic comparison of A) zeta potential, B) particle size, and C) entrapment efficiency of initial emulsifier based DMAB
formulations with emulsifier free DMAB formulations. Values are expressed as mean ¡ SD, n53. *p,0.05, significantly different from initial
formulations.
doi:10.1371/journal.pone.0113558.g003
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of lecithin can act to reduce polymer surface charge and effectively mask the
cationic charge associated with DMAB inclusion, which would explain the
findings of reduced particle charge seen in emulsifier based NP formulations.
In emulsifier free formulations, particle size increased with increasing stabilizer
concentrations, with peak particle size reaching micron levels at 0.5% and 1%
DMAB concentration (972.93¡547.71 nm and 4849.77¡313.75 nm, respectively) (Fig. 3B). These results indicate that lecithin effectively reduces interfacial
tension between organic and aqueous phases. In solvent evaporation processes,
when organic phase is added to aqueous phase in a drop wise manner, the
resultant organic droplets are stabilized by polymers formed at solute interfaces
[44]. The type of polymer, surfactant, or emulsifier used can act to alter interfacial
tensions between the organic droplets and the aqueous solution. After placement
of organic phase into aqueous phase, interfacial spreading occurs as a result of
diffusion between solvents, providing energy for NP formation [44]. NP size is
dependent on diffusion rate which is dependent on changes in the interfacial
tension between organic and aqueous phases. Lower interfacial tension equates to
smaller NP size properties [44–47]. The addition of compounds such as lecithin
act to effectively change interfacial tension which can alter particle size and NP
formation [47, 48]. Lecithin favors a higher organic phase to aqueous phase
interface [45] that, when added to organic solvents such as ethyl acetate, could
function to alter the rate of solvent diffusion and reduce particle size.
Peak drug entrapment was seen at DMAB concentrations of 1% for
formulations without emulsifier (82.91¡0.67%) (Fig. 3C). In relations to 1%
DMAB formulation carried out with emulsifier, these results equate to an almost
22% increase in NP drug loading (P,0.01). In theory, inclusion of lecithin could
act to offset surface tension allowing for fast organic phase diffusion into the
aqueous phase [49]. The alteration in interfacial tension could also function to
reduce barrier transport of drug outside of the organic phase during solvent
diffusion. Inclusion of lecithin into the polymeric shell with increasing
concentrations of DMAB resulted in a net reduction in drug entrapment
compared to its emulsifier free counterpart. Much like lecithin, DMAB can form
micelle aggregates that function through hydrophobic interactions of DMAB with
the hydrophobic core of the NP [33]. The interactions of the hydrophobic portion
of the stabilizer can function to solubilize the hydrophobic drug entrapped within
the NP core [35]. It is possible that as concentrations of both DMAB and lecithin
increased in formulations, the net rise in hydrophobic interaction resulted in
increased NP and CEL solubility leading to drug leakage and reduced drug
entrapment. Similar results were obtained by Thakkar et al. when using Span-85
as an emulsifying agent during the development of CEL microspheres [50]. In the
study, it was found that formulations using high concentrations of emulsifier (5%
w/w) and stabilizer (2% w/w) resulted in enhanced CEL solubility and dissolution,
which led to a reduction in both particle size and drug entrapment efficiency.
Previously, our lab completed formulation of diclofenac (a non-selective
NSAID) loaded PLGA-NPs using DMAB and PVA [33]. With no change in drug
amount (45 mg) or use of emulsifier, diclofenac loaded PLGA-NPs with DMAB
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or PVA exhibited negative surface charges and a peak entrapment efficiency as
high as 80.21¡1.21%. The negative NP surface charge associated with diclofenac
NP formulations using DMAB contrast with the highly positive surface charge of
DMAB formulated CEL loaded NPs found in this study. When using diclofenac,
PVA formulated NPs showed smaller negative surface charges, similar to the
negative surface charge characteristics associated with our PVA formulated CELNP formulation. In physiological conditions, diclofenac is a negatively charged
molecule which may play a role in the development of negatively charged NPs
during formulation with DMAB [51]. Conversely, at physiological pH, CEL
presents as a neutrally charged molecule [52] that, when formulated with cationic
DMAB, resulted in formation of positively charged NPs. Particle size analysis
showed a similar pattern when comparing CEL formulation results with that of
diclofenac. Diclofenac NP formulation showed a maximum increase of NP size
(189.9¡4.9 nm) using 1% w/v DMAB. Similarly, results of our CEL formulation
study demonstrated maximum NP size with 1% w/v DMAB concentration
(Fig. 3B). Measurements of entrapment efficiency showed opposite effects. For
diclofenac NPs, a linear reduction in total entrapment efficiency was seen with
regard to increasing DMAB concentrations with the lowest amount of diclofenac
entrapment occurring with 1% w/v DMAB. Conversely, maximum CEL loading
seen within this study was observed at 1% DMAB, which when compared to the
highly polarizable diclofenac [53],
the theory that higher concentrations of DMAB may increase solubility of
lipophilic drugs such as CEL, in turn leading to increases in particle size and drug
entrapment [41].

Effect of drug amount on NP characteristics
To study the effect of drug amount on NP characteristics, formulations consisting
of 0.25% DMAB concentrations were chosen based on their sufficient size and
general representation of drug entrapment and zeta potential. In conjunction with
previously formulated NP systems using 20 mg CEL, new NPs with or without
emulsifier were formulated with increasing amounts (5, 10, and 15 mg) of CEL
(Table 3). Morphological characterization of NPs formulated with (Fig. 4) and
without (Fig. 5) emulsifier at various drug amounts showed spherical shape and
size similar to what was noticed in previous formulation studies [23, 24, 54–58].
All NP formulations without emulsifier displayed significantly higher zeta
potential compared to formulations with emulsifier (Fig. 6A) (p,0.01).
Maximum zeta potential was reached in formulations of 20 mg CEL without
emulsifier (25.00¡0.18 mV). Formulations with emulsifier reached peak zeta
potential using 15 mg CEL (17.15¡0.36 mV). These results further indicate that
use of emulsifiers such as lecithin, can function to mask surface charge of the
incorporated stabilizer thereby reducing overall cationic charge associated with
DMAB formulated NPs [44].
Peak size reduction and entrapment efficiency for formulations with
(70.87¡1.24 nm and 95.55¡0.66%, respectively) and without (92.97¡0.53 nm

PLOS ONE | DOI:10.1371/journal.pone.0113558 December 12, 2014
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Table 3. Preparation method for NP formulations with differing drug amounts.
Formulation Number

Ingredients
Ethyl acetate (mL)

Water (mL)

DMAB (%
w/v)

PLGA
(mg)

Celecoxib
Acetone (mL) (mg)

Lecithin
(mg)

1

3

6

0.25

50

500

20

30

2

3

6

0.25

50

500

15

30

3

3

6

0.25

50

500

10

30

4

3

6

0.25

50

500

5

30

5

3

6

0.25

50

500

20

-

6

3

6

0.25

50

500

15

-

7

3

6

0.25

50

500

10

-

8

3

6

0.25

50

500

5

-

doi:10.1371/journal.pone.0113558.t003

and 95.93¡0.27%, respectively) emulsifier was achieved using 5 mg drug
amounts (Fig. 6B and Fig. 6C, respectively). These results indicate an important
role for drug solubility on the characterization of CEL loaded NPs.
CEL exhibits poor aqueous solubility and is categorized as a class II drug under
the biopharmaceutical classification system [59–61]. During CEL loaded NP
formulation, several techniques such as size reduction, use of emulsifier, or
surfactants can be applied to help increase the degree of drug solubility in aqueous
media and improve overall NP characteristics [62]. In applications oriented

Fig. 4. TEM images illustrating morphology of 0.25% w/v DMAB NP formulations with emulsifier at A)
5 mg drug amount, B) 10 mg drug amount, C) 15 mg drug amount, and D) 20 mg drug amount.
doi:10.1371/journal.pone.0113558.g004
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Fig. 5. TEM images illustrating morphology of 0.25% w/v DMAB NP formulations without emulsifier at
A) 5 mg drug amount, B) 10 mg drug amount, C) 15 mg drug amount, and D) 20 mg drug amount.
doi:10.1371/journal.pone.0113558.g005

toward NP production, several of these techniques are often applied in order to
increase drug solubility and prevent drug precipitating out of the NP shell. In this
study, stabilizers and an emulsifier were used to alter drug solubility and optimize
particle characteristics. The use of drug amount was also analyzed as a
measurement of solubility effects on zeta potential, particle size, and drug
entrapment. In an effort to optimize drug entrapment, drug amounts were
titrated to measure extent of effects on NP encapsulation. The solubility of a drug
is related to the ratio of drug surface area to solvent volume [62]. In particle size
reduction, surface area is increased and allows greater interactions with the solvent
which causes an increase in solubility. In conjunction with particle size reduction
via sonication, reduction in drug amount improves drug solubility by further
enhancing the surface-area-to-volume ratio. We found that when drug amount
was decreased in CEL-NP formulations, entrapment efficiency was able to achieve
over 95% loading capacitance (Fig. 6C). This success indicates the importance of
drug amount in conjunction with size reduction for the prevention of drug
precipitation and enhancement of entrapment efficiency during NP formulations.
In this study, we found that as drug amount increased to 20 mg, total
entrapment of CEL was higher in formulations with emulsifier while amounts of
15 mg and 10 mg CEL displayed increasing total drug entrapment in regard to the
emulsifier free formulation (Fig. 6C). It is possible that higher concentrations of
CEL undergo enhanced solubilization in the presence of emulsifier enabling a
larger degree of drug entrapment in the presence of higher drug amounts.
Furthermore, lecithin is a non-ionic emulsifier known to impart steric stabilizing
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Fig. 6. The effect of varying drug amounts on A) zeta potential, B) NP size, and C) entrapment efficiency. Values are expressed as mean ¡ SD, n53.
*
p,0.05, significantly different from formulations with emulsifier.
doi:10.1371/journal.pone.0113558.g006
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effects in colloidal systems, preventing particle collision and reducing drug leakage
[63, 64]. It is possible that as drug amounts increase, lecithin functions to increase
drug solubility, stabilize NP formation, and reduce drug leakage leading to an
increase in drug entrapment. The observation that larger drug amounts undergo
increased NP entrapment in the presence of lecithin may support the idea of
emulsifier use during NP production of high concentrations of lipophilic drugs.

Stability of CEL loaded PLGA-NPs
To avoid particle aggregation and coalescence, the recommended storage
temperature for PLGA-NP systems is 4 ˚C [65]. Therefore, to analyze the stability
of PLGA-NP systems, emulsions of varying drug amounts with or without
emulsifier were kept at 4 ˚C for a period of 16 weeks then characterized to
determine storage effects on zeta potential, particle size, and drug entrapment
efficiency.
Results showed that zeta potential, particle size, and entrapment efficiency were
at or below initial reported NP characterization measurements (Fig. 7 and Fig. 8).
All peak characteristic measurements after 16 weeks of cold storage were noted in
formulations that included emulsifier (Fig. 7). When compared to our initial
formulations (Fig. 6), zeta potential was reduced across all formulations
(p,0.05), with a peak zeta potential seen in formulations using 10 mg drug
amounts with emulsifier (5.92¡0.98 mV) (Fig. 7A). When analyzing particle
diameter, a peak reduction was seen in 10 mg formulations with emulsifier
(63.23¡3.33 nm). Furthermore, when compared to initial characteristic measurements, significant particle size reduction was seen in the 10 mg and 20 mg
CEL formulations with emulsifier (Fig. 7B) (p,0.01), as well as the 5 mg and
15 mg formulations without emulsifier (Fig. 8B) (p,0.01). All formulations
showed a significant reduction (p,0.01) in entrapment efficiency with the highest
level of entrapment maintained in the 5 mg formulation with emulsifier
(79.58¡0.611%) (Fig. 7C). These results indicate the possible role emulsifying
agents may have in maintenance of NP stability. The reduction of zeta potential
observed in all formulations could be a result of possible DMAB dissociation from
the NP shell after 16 weeks. Loss of DMAB would lead to reduced particle charge,
net repulsion, and stability resulting in increased drug leakage, particle size
reduction, and reduced entrapment efficiency [66]. Furthermore, the emulsifier in
our formulation may be exerting unknown effects on drug permeation and NP
aggregation, allowing for enhanced time-dependent stability of PLGA-NPs
formulated with lecithin [67].

Conclusion
In this study, we performed a solvent evaporation technique to developed and
characterize CEL loaded PLGA-NPs using varying concentrations of DMAB or
PVA as stabilizer. NPs were examined and characterized based on zeta potential,
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Fig. 7. Nanoparticle characteristic comparison of A) zeta potential, B) particle size, and C) entrapment efficiency of initial emulsifier based
formulations with those observed following 16 weeks cold storage at 4˚C. Values are expressed as mean ¡ SD, n53. *p,0.05, significantly different
from initial formulations.
doi:10.1371/journal.pone.0113558.g007
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Fig. 8. Nanoparticle characteristic comparison of A) zeta potential, B) particle size, and C) entrapment efficiency of initial emulsifier free
formulations with those observed following 16 weeks cold storage at 4˚C. Values are expressed as mean ¡ SD, n53. *p,0.05, significantly different
from initial formulations.
doi:10.1371/journal.pone.0113558.g008
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size, drug entrapment efficiency, and morphology. The results of this study
showed that the use of DMAB as stabilizer led to the development of NPs that
displayed sufficient size and stability with moderate increases in drug entrapment
when compared to plain formulation. Of the two stabilizers, DMAB proved to be
highly efficient in developing well characterized CEL loaded PLGA based NPs,
whereas PVA based formulations failed to reach optimum parameters in NP
development. Variables such as emulsifier and drug amount were also analyzed to
further optimize NP formulations. When formulations were carried out in the
presence of emulsifier, a reduction in zeta potential was noted. Emulsifier based
formulations displayed reduced surface charge as a consequence of lecithin
induced anionic interactions and masking of cationic DMAB properties indicating
that in the presence of DMAB based formulations emulsifiers such as lecithin may
act to reduce NP stability and formula optimization. Additional formula
evaluation showed that reduction in drug amount was effective at reducing
particle size and enhancing drug entrapment efficiency further elucidating the role
of drug solubility and the importance of increasing the surface-area-to-volume
ratio for effective development of CEL loaded NPs. Interestingly, while the use of
emulsifier resulted in reduced zeta potential and system stability, time-dependent
stability testing, which looked at zeta potential, size, and entrapment efficiency
after 16 weeks cold storage, showed peak particle characteristics in formulations
with emulsifier. These results may indicate that while emulsifiers, such as lecithin,
reduce overall particle charge during formulation, they could also prolong NP
system stability over an extended period of time. However, further testing is
needed to determine the extent of emulsifier effects on CEL loaded PLGA-NP
stability. Overall, the results of our study indicate that the formulation of PLGANPs using 0.25% w/v DMAB and 5 mg CEL without emulsifier creates highly
entrapped and stable NPs of a sufficient size that could function to enhance the
application of orally delivered CEL and provide a potential effective dosage form
for CEL administration.

Supporting Information
S1 Figure. TEM images of emulsifier based formulation illustrating morphology
of A) 0.1% w/v DMAB formulated NPs, B) 0.25% w/v DMAB formulated NPs, C)
0.5% w/v DMAB formulated NPs, and D) 1% w/v DMAB formulated NPs.
doi:10.1371/journal.pone.0113558.s001 (TIF)
S2 Figure. TEM images of emulsifier free formulations illustrating morphology of
A) 0.1% w/v DMAB formulated NPs, B) 0.25% w/v DMAB formulated NPs, C)
0.5% w/v DMAB formulated NPs, and D) 1% w/v DMAB formulated NPs.
doi:10.1371/journal.pone.0113558.s002 (TIF)
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